Try our Advanced Search for more refined results
Mylan Pharmaceuticals Inc, et al v. Warner Chilcott Public Limited, et al
Case Number:
15-2236
Court:
Nature of Suit:
Companies
- AARP Inc.
- Center for Medicare Advocacy Inc.
- Consumer Action
- Consumer Federation of America
- Indivior PLC
- International Brotherhood of Electrical Workers
- Mayne Pharma Group Ltd.
- Meijer Inc.
- National Association of Manufacturers
- National Health Law Program
- Rochester Drug Cooperative Inc.
- Safeway Inc.
- Warner Chilcott Limited
Government Agencies
Sectors & Industries:
-
May 03, 2017
Mylan Won't Appeal 3rd Circ. Loss On Doryx Generic
Generic-drug maker Mylan Pharmaceuticals Inc. won't be appealing the Third Circuit's decision affirming a Pennsylvania federal court's dismissal of the company's antitrust suit alleging Warner Chilcott restrained competition for acne medication Doryx, as the deadline for petitioning the U.S. Supreme Court has passed.
-
November 30, 2016
3rd Circ. Won't Rethink Mylan's Doryx Product-Hopping Loss
The Third Circuit on Wednesday rejected Mylan's request for the court to reconsider a September decision affirming a dismissal of its suit against Warner Chilcott alleging it stifled competition for acne medication Doryx by reformulating the drug.
-
October 20, 2016
FTC, Antitrust Org Ask 3rd Circ. To Rethink Doryx Decision
The Federal Trade Commission and American Antitrust Institute on Wednesday each asked the Third Circuit to rethink its dismissal of Mylan Pharmaceuticals Inc.'s product-hopping suit against Warner Chilcott Ltd. over the acne medication Doryx, arguing the court changed the Sherman Act's standard of harm and misinterpreted an array of precedent.
-
October 17, 2016
3rd Circ. Got Doryx Product-Hopping Suit Wrong, Mylan Says
Mylan on Friday asked for the Third Circuit to reconsider a September decision affirming a dismissal of its antitrust suit against Warner Chilcott over acne medication Doryx, saying if the holding is allowed to stand, it could provide a safe harbor for pharmaceutical companies to engage in product hopping.
-
September 28, 2016
Mylan Antitrust Suit Over Acne Drug Rejected By 3rd Circ.
The Third Circuit on Wednesday affirmed a Pennsylvania federal court's dismissal of Mylan's antitrust suit over the acne medication Doryx, finding that the generics maker failed to establish that Warner Chilcott and Mayne had sufficient market power in the relevant market.
-
June 29, 2016
3rd Circ. Wants Arguments Limited To Market In Doryx Row
The Third Circuit on Tuesday told counsel for Mylan Pharmaceuticals Inc., Warner Chilcott PLC and Mayne Pharma Group Ltd. that their oral arguments next month in an antitrust case over the acne medication Doryx should be limited to defining a market and proving or disputing anticompetitive conduct.
-
March 29, 2016
Warner Says Mylan Misstatements Key To Doryx Antitrust Row
Warner Chilcott and Mayne Pharma have pressed the Third Circuit to let them file an extra brief opposing Mylan's attempt to revive antitrust claims over the acne medication Doryx, arguing that Mylan made misstatements about crucial questions in the case.
-
March 17, 2016
Mylan Slams Warner's 'Overheated Rhetoric' In Doryx Row
Allowing Warner Chilcott to file a surreply in Mylan's suit accusing it of blocking generics for the acne medication Doryx by tweaking its formula would only delay Mylan's appeal of its district court loss without helping further the case, the generic drugmaker has told the Third Circuit.
-
March 02, 2016
Mylan Accused Of 'Whopping Misstatements' In Doryx Row
Warner Chilcott PLC on Wednesday ripped Mylan Pharmaceuticals Inc.'s bid to revive a suit accusing Warner of tweaking the formula of its acne medication Doryx in order to block generic competition, saying a recent brief Mylan filed with the Third Circuit contains "whopping misstatements" and unfounded accusations.
-
February 10, 2016
Mylan Pushes 3rd Circ. To Revive Doryx Product-Hopping Suit
Generic-drug maker Mylan Pharmaceuticals Inc. has urged the Third Circuit to resurrect its suit against Warner Chilcott PLC for allegedly tweaking the formula of its acne medication Doryx in order to block generic competition, saying Warner's defenses "amount to a call to abandon all antitrust review of product changes."